

Finance Committee Meeting

Wed 27 April 2022, 14:00 - 16:00

Agenda

14:00 - 14:00 **1. Standing Items**

0 min

1.1. Welcome and Introductions

Rhian Thomas

1.2. Apologies for Absence

Rhian Thomas

1.3. Declarations of Interest

Rhian Thomas

1.4. Minutes of the previous Committee meeting – 23 March 2022

Rhian Thomas

1.5. Action log following the meeting held on 23 March 2022

Rhian Thomas

1.6. Chair's Actions since previous meeting

Rhian Thomas

14:00 - 14:00 **2. Items for Review and Assurance**

0 min

2.1. Financial Report – Month 12

Paul Emmerson

2.2. Cost Reduction Programme


Catherine Phillips

2.3. Financial Tracker System for Corporate and Clinical Board

Catherine Phillips/Caroline Bird

2.4. Escalation of Corporate Directorates and Clinical Boards

Caroline Bird

 2.4 Escalation of Clinical Boards and Corporate Departments.pdf (4 pages)

2.5. Capital Programme

Catherine Phillips

Mohamed Saif
04/20/2022 15:14:24

14:00 - 14:00 **3. Items for Approval / Ratification**
0 min

3.1. Revenue and Capital Funding and Service Implications

Catherine Phillips/Caroline Bird

14:00 - 14:00 **4. Items for Information and Noting**
0 min

4.1. Financial Monitoring Returns – Month 12

Hywel Pullen

14:00 - 14:00 **5. AOB**
0 min

14:00 - 14:00 **6. Review and Final Closure**
0 min

6.1. Items to be deferred to Board / Committee

Rhian Thomas

6.2. Date and time of next meeting

Wednesday 25 May 2022 at 2pm Via MS Teams

Report Title:	Escalation of Clinical Boards and Corporate Departments		Agenda Item no.	2.4
Meeting:	Finance Committee	Public	x	Meeting Date:
		Private		
Status <i>(please tick one only):</i>	Assurance	x	Approval	Information
Lead Executive:	Interim Chief Operating Officer			
Report Author (Title):	Interim Chief Operating Officer			

Main Report

Background and current situation:

Executive Performance Reviews with the Clinical Boards form an integral part of the UHB's current Performance Management Framework. Whilst these reviews were stood down during the covid pandemic, Management Executive agreed on 11th April 2022 for reviews to be re-instated from May or June 2022.

The approach and structure originally agreed in April 2018 has been updated to ensure the regular reviews focus discussions on the key in-year priorities for the Health Board. Going forward, there will be ten operational performance reviews, chaired by the Chief Operating Officer, and two service reviews, chaired by the Chief Executive Officer, each year.

Finance and operational delivery will be covered in all ten operational reviews, with the Chief Operating Officer and Finance Director attending. In addition, performance against quality indicators (five reviews per annum) and performance against workforce indicators (five reviews per annum) will be also form part of the agenda. The Executive Nurse Director and/or Executive Medical Director will be in attendance when quality is on the agenda and the Executive Director of People and Culture will be in attendance for workforce.

Reporting and escalation arrangements will remain as previously agreed. Reporting arrangements will be through action notes. An 'Assessment of Performance and level of assurance' report – see Appendix 1 – will be completed at the time of the performance review. The lead Executive for each performance area will make a judgement on performance levels for their respective area and the Chief Operating Officer, as Chair, will make a judgement on progress against previously agreed actions / milestones, the complexity of the challenge and the overall level of assurance and recommendation to Management Executive.

The feedback to Management Executive will allow the Chief Executive Officer to form a view on the overall level of assurance for each Clinical Board. Where it is felt performance is not satisfactory or progressing and assurance is deemed limited escalation is at Chief Executive Officer Level – with the Chief Executive Officer either attending the next Operational Performance Review or scheduling an extraordinary meeting. This escalation would remain in place until such time that the performance is recovered to a level acceptable to the Chief Executive Officer.

Executive Director Opinion and Key Issues to bring to the attention of the Board/Committee:

- The Executive Performance Review structure with Clinical Boards has been updated to ensure the regular reviews focus discussions on the key in-year priorities for the Health Board. There will be ten operational performance reviews each year. Finance will be considered in all ten reviews
- Reporting and escalation arrangements will remain as previously agreed in April 2018 i.e.
 - Reporting arrangements will be through action notes.
 - An 'Assessment of Performance and level of assurance' report will be completed by the relevant Executives at the time of the review and feedback to Management Executive.

The feedback to Management Executive will allow the Chief Executive Officer to form a view on the overall level of assurance for each Clinical Board. Where it is felt performance is not satisfactory or progressing and assurance is deemed limited escalation is at Chief Executive Officer Level.

- A summary of the level of assurance for all Clinical Boards will be shared at Committee meetings

Recommendation:

The Committee is requested to:

- NOTE the performance review and escalation arrangements for Clinical Boards for 2022-23 onwards

Link to Strategic Objectives of Shaping our Future Wellbeing:

Please tick as relevant

1. Reduce health inequalities		6. Have a planned care system where demand and capacity are in balance	
2. Deliver outcomes that matter to people		7. Be a great place to work and learn	
3. All take responsibility for improving our health and wellbeing		8. Work better together with partners to deliver care and support across care sectors, making best use of our people and technology	
4. Offer services that deliver the population health our citizens are entitled to expect		9. Reduce harm, waste and variation sustainably making best use of the resources available to us	x
5. Have an unplanned (emergency) care system that provides the right care, in the right place, first time		10. Excel at teaching, research, innovation and improvement and provide an environment where innovation thrives	

Five Ways of Working (Sustainable Development Principles) considered

Please tick as relevant

Prevention	Long term	Integration	Collaboration	Involvement
------------	-----------	-------------	---------------	-------------

Impact Assessment:

Please state yes or no for each category. If yes please provide further details.

Risk: No

Safety: No

Financial: No

Workforce: No

Legal: No

Reputational: No

Socio Economic: No

*Monitored Sarah
On 20/2022 15:44:24*

Equality and Health: No	
Decarbonisation: No	
Approval/Scrutiny Route:	
Committee/Group/Exec	Date:

Mohamed Sarah
04/20/2022 15:14:24

Clinical Board Performance Reviews
Assessment of performance and level of assurance

Month:	August
---------------	--------

Clinical Board:	
------------------------	--

Progress against previously agreed actions:

Has the Clinical Board made sufficient progress against previously agreed actions / milestones	Yes / No
--	----------

Assurance on current performance levels:

	In-month assessment	Justification for current assurance level
Finance	Limited	
Operational Delivery	Substantial	
Quality	-	
Workforce	Adequate	

Trend of performance delivery - assurance levels over the last four months:

	Current month	July	June	May
Finance	Limited	Adequate	Adequate	Substantial
Activity	Substantial	Adequate	Adequate	Adequate
Quality	-	Substantial	-	Limited
Workforce	Substantial	-	Adequate	-
Overall	Adequate	Adequate	Adequate	Adequate

Complexity of the Challenge:

--

Chair's recommendation:

Overall level of assurance	Limited / Adequate / substantial
Recommendation to Management Executive:	
Decision following Management Executive:	

Mohammed Saleh
04/20/2022 11:14:24